Loading...
*  Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer - The ASCO Post
According to an analysis reported by Amanda Phipps, PhD, MPH, Assistant Professor of Epidemiology at the University of Washington and Assistant Member at Fred Hutchinson Cancer Research Center, Seattle, and colleagues in the Journal of Clinical Oncology, patients with stage III colon cancer who ever smoked had significantly reduced disease-free survival compared with never-smokers.1 The association between smoking and reduced disease-free survival was most marked in patients with BRAF wild-type or KRAS mutant colon cancer. Prior studies have indicated that cigarette smoking is associated with a modestly increased risk for colon cancer, particularly after long durations or high levels of exposure.. Study Details. The study involved 1,968 patients with stage III disease from the North Central Cancer Treatment Group phase III trial N0147 examining FOLFOX (infusional fluorouracil, leucovorin, ...
http://www.ascopost.com/issues/june-10-2013/smoking-linked-to-shorter-disease-free-survival-in-stage-iii-colon-cancer/
*  Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer - The ASCO Post
Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease-free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual Meeting, are only part of the story. According to secondary data introduced at the 2015 Breast Cancer Symposium, certain subsets derived even greater benefits,2 including those with hormone receptor-positive disease and those pretreated with trastuzumab (Herceptin) sequentially.. "ExteNET is the first study to show a statistically significant improvement in invasive disease-free survival in the intent-to-treat population," said Arlene Chan, MD, of the Breast Cancer Research Centre, Western Australia, and Curtin University in Perth. "Furthermore, in the centrally confirmed HER2-positive cohort, we are ...
http://www.ascopost.com/issues/november-25-2015/neratinib-improves-disease-free-survival-in-early-stage-her2-positive-breast-cancer/
*  Dissecting the Bull: June 2008
In the first study, the primary endpoint was response rate, and secondary endpoints were time to disease progression, progression-free survival, overall survival and safety. This was met with patients receiving amrubicin demonstrating an overall response rate of 34 percent, compared to 3.8 percent of patients receiving topotecan and the median progression-free survival time for amrubicin patients is 138 days compared to 106 days for topotecan. In the second multi-center international study, patients with SCLC who were refractory to first-line platinum based chemotherapy were treated with IV amrubicin . The primary endpoint was response rate, and secondary endpoints were time to disease progression, progression-free survival, overall survival and safety. The overall response rate for the study was 17.4 percent with one complete response, ...
http://openicon.blogspot.com/2008_06_01_archive.html
*  Most recent papers with the keyword Ph+ acute lymphoblastic leukemia | Read by QxMD
The treatment of Ph-positive acute lymphoblastic leukemia (Ph+ ALL) has entranced tyrosine kinase inhibitors (TKIs) era. Currently both imatinib and dasatinib are registered as the front-line treatment for Ph+ ALL, and the other 2nd-generation TKIs are suggested as an alternative for those who failed the first-line treatment. However, it remains unclear who could benefit from the 2nd-generation TKIs as the first-line treatment for Ph+ ALL. In this study we compared the efficacy and safety of the 1st and 2nd-generation TKIs in the front-line treatment of Ph+ ALL and found a trend toward better disease-free survival (DFS) in the 2nd-generation TKIs group, though no significant difference in early response and long-term survival between the two groups ...
https://www.readbyqxmd.com/keyword/119924
*  Analysis of progression free survival versus overall survival in melanoma. Analysis of progression free survival versus overall...
Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA. Dr Keith Flaherty talks with ecancer at the 2013 European Cancer Congress in Amsterdam about a study that compared the progression free survival and overall survival in melanoma clinical trials with trametinib, ipilimumab and vemurafenib.. The relationship between PFS and OS was established by looking at the hazard ratio reported in each of the studies and a series of sensitivity analysis.. ...
http://ecancer.org/video/2318/analysis-of-progression-free-survival-versus-overall-survival-in-melanoma.php
*  Disease-free survival curve (A) and overall survival cu | Open-i
Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A),
https://openi.nlm.nih.gov/detailedresult.php?img=PMC3140667_gnl-5-204-g002&req=4
*  All Bisphophonates Reduce Recurrence Risk the Same Amount
Bonefos and Boniva are pills taken by mouth. The zoledronic acid is given as an IV infusion through a needle inserted in a vein. The researchers wanted to see if one of the bisphosphonates would improve disease-free survival more than the others. Disease-free survival is how long the women lived without the cancer coming back. After about 5.4 years of follow-up, the researchers found that 88% of the women were living and had not had a recurrence. This rate was the same no matter which bisphosphonate the women got. When the researchers looked at the women by the type of breast cancer they had been diagnosed with, they found the disease-free survival rates varied slightly by cancer type. Still, when looking at individual cancer types, all the bisphosphonates offered the same benefits. The 5-year overall survival rate was 93%. This means that ...
http://www.breastcancer.org/research-news/all-bisphosphonates-reduce-risk-the-same
*  Search of: 14701768 [PUBMED-IDS] - List Results - ClinicalTrials.gov
response rate, stable disease rate evaluated by RECIST criteria, median overall and disease-free survival time, 1-year overall and disease-free survival rate, toxicity and time to disease ...
https://clinicaltrials.gov/search/term=14701768%20%5BPUBMED-IDS%5D
*  Disease-Free Survival Estimates for Ovarian Cancer Improve Over Time
The probability of staying disease-free improves dramatically for ovarian cancer patients who already have been disease-free for a period of time, and time elapsed since remission should be taken into account when making follow-up care decisions.
http://www.upmc.com/media/newsreleases/2014/pages/aacr-disease-free-estimates-ovarian-cancer.aspx
*  Penny PayDay: Galena Bio (Nasdaq: GALE) NeuVax Phase 1/2 boosters improve disease-free survival at 60 month
Initially, patients in the trials were given a series of up to six inoculations of NeuVax dosed once a month. As the trials progressed, the physicians noticed that E75-specific immunity waned after this initial monthly Primary Vaccine Series (PVS) and translated to late recurrences of cancer in some patients. This declining immunity was identified by monitoring the level of CD8 T-cells in each of the patients. Through this evaluation, it became clear that immunological boosters would keep the level of circulating E75-specific CD8+ T cells elevated during the conduct of the trial. As a result of this finding, a voluntary booster program was added to the trials to maintain long-term immunity following the initial monthly PVS ...
http://penny-payday.blogspot.com/2012/06/galena-bio-nasdaq-gale-neuvax-phase-12.html
*  Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer ...
SAN ANTONIO, Dec. 07, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of care agents demonstrated prolonged progression-free survival (PFS) in a subgroup of patients participating in two ongoing Phase 1b studies. Results from a subgroup analysis from these tucatinib combination studies showed 22 percent…
https://culthub.com/entertainment/prolonged-progression-free-survival-reinforces-tucatinibs-potential-for-patients-with-advanced-her2-metastatic-breast-cancer/39449
*  Med-Chemist: August 2012
In the Perifosine 228 trial, 1 patient achieved a partial response (objective response rate, 4%; 95% confidence interval, 0.7%-20%), and 11 patients (46%) had stable disease as their best response. The median progression-free survival was 14.2 weeks (95% confidence interval, 7.7-21.6 weeks). In the Perifosine 231 trial, 5 patients achieved a partial response (objective response rate, 10%; 95% confidence interval, 4.5%-22.2%) and 16 patients (32%) had stable disease as their best response. The median progression-free survival was 14 weeks (95% confidence interval, 12.9, 20.7 weeks). Overall, perifosine was well tolerated, and there were very few grade 3 and 4 events. The most common toxicities included nausea, diarrhea, musculoskeletal pain, and fatigue. ...
http://www.med-chemist.com/2012_08_01_archive.html
*  Laboratory | Til Dawn Papercrafts
All analyses were performed based on the intention-to-treat principle, irrespective of process compliance, but five individuals in the intermediate-dosage group and four in the high-dosage group were excluded as ineligible . Cox regression analysis was used to investigate the effects of treatment group and covariates on event-free survival and general survival. These analyses were performed […]. ...
http://www.tildawnpapercrafts.com/category/laboratory/
*  Plus it
The treatment of children with rhabdomyosarcoma by a combination of surgery, radiotherapy, and chemotherapy has resulted in an improved disease-free survival time. Of 11 children with regional disease eight (72%) remained well, with no evidence of disease, four to 36 months after diagnosis. Chemotherapy for one year with vincristine, actinomycin D, and cyclophosphamide was well tolerated during and after radical radiotherapy and surgery. The natural history of this malignancy has been altered in these patients when compared with that in a historical group of 17 children, only two of whom remain alive. There has been no serious short-term toxicity so far. ...
http://www.bmj.com/content/1/6004/247
*  Health and Medical Sources
The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation is indicated especially after breast conserving surgery and substantially improves local relapse rates and in many circumstances also overall survival. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects ...
http://healthandmedicalsources.com/?action=breast
*  a) Overall survival (OS) and (b) progression-free surv | Open-i
(a) Overall survival (OS) and (b) progression-free survival (PFS) assessed by Kaplan-Meier methodology in the overall population of patients with unresectable
https://openi.nlm.nih.gov/detailedresult.php?img=PMC4317960_cas0105-1584-f3&req=4
*  Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights - Oncoletter, Webportal für Onkologie und onkologische...
566 pts were contemporaneously randomised: 189 SOC+DocP (the last of 592 SOC+DocP pts) & 377 SOC+AAP (the first of 960 SOC+AAP pts). Groups were well balanced with 342 (60%) M1; 429 (76%) Gleason 8-10; 449 (79%) WHO PS 0; median age 66yr & PSA 56ng/ml. At median follow up 4 yr, there were 149 deaths (45 SOC+Doc, 111 SOC+AAP): survival HR 1.16 (0.82-1.65); failure free survival HR = 0.51 (0.39-0.67); progression free survival HR 0.65 (0.48-0.88); metastases free survival HR 0.77 (0.57-1.03); & SRE HR 0.83 (0.55-1.25). There was no heterogeneity by baseline M0/M1. Grade 3, 4, 5 toxicity was 36%, 13%, 1% SOC+DocP, & 40%, 7%, 1% SOC+AAP. Subsequent treatments varied by arm, with much crossing after progression.. ...
https://www.oncoletter.ch/esmo-2017/richard-cathomas-urogenital-carcinoma.html
*  Disease-free (A, C, and E) and overall (B, D, and F) su | Open-i
Disease-free (A, C, and E) and overall (B, D, and F) survival of the 87 patients with endometrial cancer according to CRH (A and B), CRHR1 (C and D), and CRHR2
https://openi.nlm.nih.gov/detailedresult.php?img=PMC4215916_igj-24-1549-g005&req=4
*  Where Can I Buy PhenQ? Independent Review Site - F*CK FAT
Reviews of the best places to buy PhenQ. Make sure you're getting quality product. Does GNC, Amazon or Walmart sell it? Are there coupons and price savings?
https://fckfat.com/buy-phenq/
*  Search of: 'severe congenital neutropenia' - List Results - ClinicalTrials.gov
Disease-free survival and infection assessed monthly for 6 months, every 3 months for 2 years, every 6 months for 1 year, and then yearly for 5 years post ...
https://clinicaltrials.gov/ct2/results?cond=%22severe+congenital+neutropenia%22&show_flds=Y
*  Search of: 24383844 [PUBMED-IDS] - List Results - ClinicalTrials.gov
Prognostic significance for complete response, overall survival, and relapse-free survival of total and relative expression levels (variant/wild type ratios) for each ...
https://clinicaltrials.gov/search/term=24383844%20%5BPUBMED-IDS%5D
*  Os 10 melhores hotéis: Londres 2017 (com preços e fotos) - TripAdvisor
Melhores hotéis: Londres no TripAdvisor: veja 94.124 dicas e avaliações, 33.456 fotos e ótimas ofertas e preços para 30 hotéis: Londres, Inglaterra, Reino Unido.
https://www.tripadvisor.com.br/Hotels-g186338-London_England-Hotels.html
*  Os 10 melhores hotéis: Madri 2017 (com preços e fotos) - TripAdvisor
Melhores hotéis: Madri no TripAdvisor: veja 45.457 dicas e avaliações, 24.812 fotos e ótimas ofertas e preços para 30 hotéis: Madri, Espanha.
https://www.tripadvisor.com.br/Hotels-g187514-Madrid-Hotels.html
*  ಬ್ಲ್ಯೂಟೂತ್ - ವಿಕಿಪೀಡಿಯ
ಜನವರಿ 2005ರಲ್ಲಿ, Lasco.A ಎಂದು ಹೆಸರಾದ ಸಂಚಾರಿ ದೂರವಾಣಿ ಜಾಹಿರಾತುರೂಪಿ ವರ್ಮ್‌ವೊಂದು Symbian OS (ಸೀರೀಸ್‌ 60 ವೇದಿಕೆ) ಬಳಸುವ ಸಂಚಾರಿ ದೂರವಾಣಿಗಳನ್ನು ಗುರಿಯಾಗಿಟ್ಟುಕೊಂಡು Bluetooth-ಸಶಕ್ತ ಸಾಧನಗಳನ್ನು ಬಳಸಿಕೊಂಡು ವೃದ್ಧಿಯಾಗತೊಡಗಿದುದಲ್ಲದೇ ಮತ್ತು ಇತರ ಸಾಧನಗಳಿಗೆ ಹರಡತೊಡಗಿತು. ಇದೊಂದು ಸ್ವಯಂ-ಸ್ಥಾಪಕ ವರ್ಮ್‌ ಆಗಿದ್ದು ಇನ್ನೊಂದು ಸಂಚಾರಿ ದೂರವಾಣಿ ಬಳಕೆದಾರರು ಇನ್ನೊಂದು ಸಾಧನದಿಂದ (ವೆಲಾಸ್ಕೊ.ಸಿಸ್‌) ಕಡತ ವರ್ಗಾವಣೆಗೆ ಒಪ್ಪಿಗೆ ಸೂಚಿಸಿದೊಡನೆ ...
https://kn.wikipedia.org/wiki/%E0%B2%AC%E0%B3%8D%E0%B2%B2%E0%B3%8D%E0%B2%AF%E0%B3%82%E0%B2%9F%E0%B3%82%E0%B2%A4%E0%B3%8D